These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

557 related articles for article (PubMed ID: 28147928)

  • 1. Pembrolizumab-induced myasthenia gravis: A fatal case report.
    March KL; Samarin MJ; Sodhi A; Owens RE
    J Oncol Pharm Pract; 2018 Mar; 24(2):146-149. PubMed ID: 28147928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A case of myasthenia gravis and myositis induced by pembrolizumab].
    Noda T; Kageyama H; Miura M; Tamura T; Ito H
    Rinsho Shinkeigaku; 2019 Aug; 59(8):502-508. PubMed ID: 31341124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients.
    Nguyen BH; Kuo J; Budiman A; Christie H; Ali S
    Melanoma Res; 2017 Apr; 27(2):152-154. PubMed ID: 27776019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab-induced Ocular Myasthenia Gravis with Anti-titin Antibody and Necrotizing Myopathy.
    Onda A; Miyagawa S; Takahashi N; Gochi M; Takagi M; Nishino I; Suzuki S; Oishi C; Yaguchi H
    Intern Med; 2019 Jun; 58(11):1635-1638. PubMed ID: 30713313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Re-Administration of Pembrolizumab for Urothelial Carcinoma after immune-Related Myasthenia Gravis : A Case Report].
    Kurokawa M; Shimizu K; Kitabayashi R; Ogawa K; Okada Y; Kubo K; Yamaguchi D; Okubo K
    Hinyokika Kiyo; 2022 Sep; 68(9):295-300. PubMed ID: 36199208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors.
    Makarious D; Horwood K; Coward JIG
    Eur J Cancer; 2017 Sep; 82():128-136. PubMed ID: 28666240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Refractory myasthenia gravis exacerbation triggered By pembrolizumab.
    Earl DE; Loochtan AI; Bedlack RS
    Muscle Nerve; 2018 Apr; 57(4):E120-E121. PubMed ID: 29193151
    [No Abstract]   [Full Text] [Related]  

  • 8. Managing suspected myasthenia gravis and myositis induced by pembrolizumab in a Jehovah's Witness sarcoma patient.
    Hutchinson A; Eskens D; Chan A; Bhargava A; Bycroft R
    J Oncol Pharm Pract; 2024 Jul; 30(5):950-953. PubMed ID: 38523425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myasthenia triggered by immune checkpoint inhibitors: New case and literature review.
    Gonzalez NL; Puwanant A; Lu A; Marks SM; Živković SA
    Neuromuscul Disord; 2017 Mar; 27(3):266-268. PubMed ID: 28109638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab.
    Lau KH; Kumar A; Yang IH; Nowak RJ
    Muscle Nerve; 2016 Jun; 54(1):157-61. PubMed ID: 27065302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report.
    Kamo H; Hatano T; Kanai K; Aoki N; Kamiyama D; Yokoyama K; Takanashi M; Yamashita Y; Shimo Y; Hattori N
    BMC Neurol; 2019 Aug; 19(1):184. PubMed ID: 31382909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myasthenia gravis exacerbation associated with pembrolizumab.
    Zhu J; Li Y
    Muscle Nerve; 2016 Sep; 54(3):506-7. PubMed ID: 26802533
    [No Abstract]   [Full Text] [Related]  

  • 13. Pembrolizumab-induced myasthenia gravis-like disorder, ocular myositis, and hepatitis: a case report.
    Tian CY; Ou YH; Chang SL; Lin CM
    J Med Case Rep; 2021 Apr; 15(1):244. PubMed ID: 33926558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab in the treatment of pembrolizumab-induced myasthenia gravis.
    Crusz SM; Radunovic A; Shepherd S; Shah S; Newey V; Phillips M; Lim L; Powles T; Szlosarek PW; Shamash J; Rashid S
    Eur J Cancer; 2018 Oct; 102():49-51. PubMed ID: 30138772
    [No Abstract]   [Full Text] [Related]  

  • 15. Cascade of immunologic adverse events related to pembrolizumab treatment.
    Dhenin A; Samartzi V; Lejeune S; Seront E
    BMJ Case Rep; 2019 Jun; 12(6):. PubMed ID: 31167767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myositis/Myasthenia after Pembrolizumab in a Bladder Cancer Patient with an Autoimmunity-Associated HLA: Immune-Biological Evaluation and Case Report.
    Botta C; Agostino RM; Dattola V; Cianci V; Calandruccio ND; Bianco G; Mafodda A; Maisano R; Iuliano E; Orizzonte G; Mazzacuva D; Falzea AC; Saladino RE; Giannicola R; Restifo G; Aguglia U; Caraglia M; Correale P
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34200673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myasthenia Gravis Associated With Programmed Death-1 (PD-1) Receptor Inhibitor Pembrolizumab: A 40-day Case Report.
    Ziobro AS; LaPlante RL; DeMari SR; Clark LM; Kingsley DJ; Smith AJ
    J Pharm Pract; 2021 Feb; 34(1):166-170. PubMed ID: 33143531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spontaneous development of myasthenia gravis and myositis following treatment with pembrolizumab: a case report.
    Kiaei B; Chaudhry M; Banerjee S; Brewer J; Chen Y; Khasiyev F; Guzman MA; Hayat G
    BMC Neurol; 2024 Jun; 24(1):184. PubMed ID: 38824498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous pembrolizumab-induced myasthenia gravis and myocarditis in a patient with metastatic bladder cancer: A case report.
    Takai M; Kato D; Iinuma K; Maekawa YM; Nakane K; Tsuchiya T; Yokoi S; Koie T
    Urol Case Rep; 2020 Jul; 31():101145. PubMed ID: 32190548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab-associated ocular myasthenia gravis.
    Liu Q; Ayyappan S; Broad A; Narita A
    Clin Exp Ophthalmol; 2019 Aug; 47(6):796-798. PubMed ID: 30859689
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 28.